drugset / Trial / NCT07138274

Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS

NCT07138274

Phase 2 Not yet recruiting 90 enrolled Mayo Clinic
RandomizedParallel-groupDouble-blindTreatment

Summary

single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.

Timeline

Start
2026-08
Primary completion
2031-06
Completion
2031-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Metyrapone Small molecule 1000 mg Oral